Allosteric Modulation of Cannabinoid Receptor 1—Current Challenges and Future Opportunities

Abstract

The cannabinoid receptor type 1 (CB1R), a G protein-coupled receptor (GPCR), plays an essential role in the control of many physiological processes such as hunger, memory loss, gastrointestinal activity, catalepsy, fear, depression, and chronic pain. Therefore, it is an attractive target for drug discovery to manage pain, neurodegenerative disorders, obesity, and substance abuse. However, the psychoactive adverse effects, generated by CB1R activation in the brain, limit the use of the orthosteric CB1R ligands as drugs. The discovery of CB1R allosteric modulators during the last decade provided new tools to target the CB1R. Moreover, application of the site-directed mutagenesis in combination with advanced physical methods, especially X-ray crystallography and computational modeling, has opened new horizons for understanding the complexity of the structure, function, and activity of cannabinoid receptors. In this paper, we present the latest advances in research on the CB1R, its allosteric modulation and allosteric ligands, and their translational potential. We focused on structural essentials of the cannabinoid 1 receptor- ligand (drug) interactions, as well as modes of CB1R signaling regulation.

Cannabinoids for fibromyalgia pain: a critical review of recent studies (2015–2019)

“…In contrast, CBD, a non-psychoactive component of cannabis products, has anti-inflammatory, anti-anxiety, and analgesic effects (Stith et al 2019 ). Although THC and CBD both elicit pharmacological effects through interactions with cannabinoid CB1 and CB2 receptors, THC is a receptor partial agonist, while CBD is a negative allosteric modulator of the CB1 receptor (Hryhorowicz et al 2019 ). Due to their varying properties and molecular interactions, the relative proportion of THC to CBD in cannabis products determines the type of effect, pharmacokinetics, and adverse effects associated with each unique strain (Madras 2019 ).…”

Cannabinoid Receptors: An Update on Cell Signaling, Pathophysiological Roles and Therapeutic Opportunities in Neurological, Cardiovascular, and Inflammatory Diseases

“…These studies have aided greatly in deciphering the endocannabinoid system in the molecular and the physiological realms [ 18 , 627 ]. Recent studies have brought to light the versatility and malleability of context-dependent CB1R signaling [ 628 , 629 , 630 ]. Identifying factors and conditions that could regulate CB1R expression and CNR1 gene expression could therefore help circumvent the need for direct CB1R agonists/antagonists.…”

On the Role of Central Type-1 Cannabinoid Receptor Gene Regulation in Food Intake and Eating Behaviors

“…CB 1 R is one of the most abundant seven transmembrane G protein-coupled receptor of the class A [ 46 ]. It is prominently expressed in the central nervous system (CNS) [ 47 ] and has attracted great attention as a modulator of different brain functions including appetite, fear, anxiety and pain [ 48 , 49 , 50 ]. The ECS, as a whole, is comprised of (1) the endocannabinoids (eCBs) anandamide ( N -arachidonoyl-ethanolamine) and 2-arachidonoylglycerol, which are physiological ligands for cannabinoid and non-cannabinoid receptors; (2) the cannabinoid receptors and non-cannabinoid receptors, such as transient receptor potential vanilloid 1 channels [ 51 , 52 ]; and (3) enzymes responsible for the biosynthesis and hydrolysis of eCBs.…”